Literature DB >> 15816591

Impact of patient age on propofol consumption during propofol-remifentanil anaesthesia.

S Kreuer1, J U Schreiber, J Bruhn, W Wilhelm.   

Abstract

BACKGROUND: This study was designed to investigate the impact of patient age on propofol consumption and recovery time using a propofol-remifentanil anaesthetic standardized with Narcotrend EEG monitoring. The Narcotrend is a monitor for measuring the depth of anaesthesia based upon a six-letter classification from A (awake) to F (increasing burst suppression) including 14 substages.
METHODS: In 200 patients scheduled for minor orthopaedic surgery Narcotrend EEG electrodes were positioned on the patient's forehead as recommended by the manufacturer. Anaesthesia was induced with remifentanil 0.4 microg kg(-1) min(-1) and 2 mg kg(-1) propofol. Immediately after intubation remifentanil was reduced to a constant rate of 0.2 microg kg(-1) min(-1) whereas a propofol infusion was now started at 3 mg kg(-1) h(-1) and then adjusted accordingly to achieve a target Narcotrend stages of D(0-2) indicating general anaesthesia. At the end of surgery the propofol and remifentanil infusions were stopped without tapering, the time to unstimulated opening of eyes was determined, and the propofol consumption (given as mg kg(-1) h(-1)) was calculated from the total amount of infused propofol but without the induction bolus, from the actual body weight and the duration of propofol infusion. Furthermore, a linear regression analysis was applied for propofol consumption vs. age.
RESULTS: The ages of the patients studied ranged from 16 to 83 yr old and patients were classified as ASA I-III. Propofol consumption significantly decreased with the patients' age: 30 yr of age or below the propofol consumption was calculated as 5.9 +/- 1.7 mg kg(-1) h(-1), for 31-50 yr as 5.4 +/- 1.8 mg kg(-1) h(-1), for 51-70 yr as 4.5 +/- 1.7 mg kg(-1) h(-1) and above 70 yr as 3.5 +/- 1.4 mg kg(-1) h(-1). Linear regression analysis revealed propofol (mg kg(-1) h(-1)) = 9.136 - (0.0597 x age (yr)); R = 0.53. Concomitantly, the recovery time to opening of eyes increased with the patients' age: < or = 30 yr, 7.4 +/- 3.7 min; 31-50 yr, 9.5 +/- 4.0 min; 51-70 yr, 9.8 +/- 4.1 min; and > or = 71 yr, 14.9 +/- 12.1 min.
CONCLUSIONS: We conclude that with Narcotrend guidance, mean propofol consumption and recovery times are age dependent. However, as a result of large inter-individual variability, age per se does not allow a prediction of individual propofol need or recovery time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816591     DOI: 10.1017/s0265021505000232

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  6 in total

1.  [Target-controlled infusion (TCI): clinical tool or scientific toy?].

Authors:  W Wilhelm
Journal:  Anaesthesist       Date:  2008-03       Impact factor: 1.041

2.  [EEG-adjusted target-controlled infusion : Propofol target concentration with different doses of remifentanil].

Authors:  N Büttner; B Schultz; U Grouven; A Schultz
Journal:  Anaesthesist       Date:  2010-02       Impact factor: 1.041

Review 3.  Monitored anaesthesia care in the elderly: guidelines and recommendations.

Authors:  Margaret Ekstein; Doron Gavish; Tiberiu Ezri; Avi A Weinbroum
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 4.  Delayed arousal.

Authors:  Zirka H Anastasian; Eugene Ornstein; Eric J Heyer
Journal:  Anesthesiol Clin       Date:  2009-09

5.  Confounding factors to predict the awakening effect-site concentration of propofol in target-controlled infusion based on propofol and fentanyl anesthesia.

Authors:  Shun-Ming Chan; Meei-Shyuan Lee; Chueng-He Lu; Chen-Hwan Cherng; Yuan-Shiou Huang; Chun-Chang Yeh; Chan-Yang Kuo; Zhi-Fu Wu
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

6.  Bispectral index to guide induction of anesthesia: a randomized controlled study.

Authors:  Dirk Rüsch; Christian Arndt; Leopold Eberhart; Scarlett Tappert; Dennis Nageldick; Hinnerk Wulf
Journal:  BMC Anesthesiol       Date:  2018-06-15       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.